Benefits and risks of interferon therapy for hepatitis B.

@article{Perrillo2009BenefitsAR,
  title={Benefits and risks of interferon therapy for hepatitis B.},
  author={Robert P. Perrillo},
  journal={Hepatology},
  year={2009},
  volume={49 5 Suppl},
  pages={S103-11}
}
UNLABELLED Alpha interferon is the only licensed drug for hepatitis B with immunomodulatory as well as viral inhibitory properties. Potential advantages of interferon compared to nucleoside analogs include a lack of drug resistance, a finite and defined treatment course, and a higher likelihood for hepatitis B surface antigen (HBsAg) clearance. Approximately 30% of hepatitis B e antigen (HBeAg)-positive and 40% of HBeAg-negative cases have a sustained virological response (when defined as HBeAg… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 79 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 55 references

Hepatitis B virus surface antigen levels—a guide to sustained response to pegylated interferon alfa-2a in HBeAg-negative patients

  • MR Brunetto, F Moriconi, F Bonino, GKK Lau, P Farci, C Yurdaydin
  • HEPATOLOGY
  • 2009
1 Excerpt

Early HBsAg loss during peginterferon alpha-2b therapy predicts HBsAgloss- Results of a long-term follow-up study in chronic hepatitis B [Abstract]. HEPATOLOGY 2008;48:723A

  • EH Buster, HJ Flink, H Simsek, EJ Heathcote, S Sharmila, GE Kitis
  • 2008
1 Excerpt

HBV genotypes are the strongest predictors of response to interferonalfa treatment: multivariate evaluation in 1229 hepatitis B patients [Abstract

  • A Erhardt, AD Ludwig, M Brunetto, F van Boemmel, E Wolf, T Goebel
  • HEPATOLOGY
  • 2008
1 Excerpt

Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40kD) with or without lamivudine: Results of 4-year follow-up [Abstract

  • P Marcellin, T Piratvisuth, M Brunetto, F Bonino, GKK Lau, P Farci
  • J Hepatol
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…